NASDAQ: ONTX was downgraded by Zacks Investment Research  from a “buy” score to a “hold” score in a research note issued to investors on Thursday, reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It concentrates on finding and creating little molecule medicine candidates to deal with cancer. The Firm‘s products under various phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts also recently commented on the company. Noble Financial editioned a “get” score and also provided a $11.00 rate objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also established a “buy” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day moving typical rate of $2.90 and a two-hundred day relocating average price of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) earnings per share for the quarter, covering analysts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an unfavorable net margin of 8,294.27%. The company had earnings of $0.06 million during the quarter, contrasted to the agreement price quote of $0.06 million. During the very same quarter in the previous year, the company published ($ 0.45) EPS. En masse, research experts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the present year.

A variety of hedge funds have recently dealt shares of ONTX. GSA Funding Partners LLP purchased a new setting in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Funding Administration LP bought a new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP bought a brand-new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as various other institutional financiers have 13.36% of the company’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which takes part in the recognition and growth of oncology therapeutics. It focuses on uncovering and creating little molecule medication candidates to treat cancer. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Get a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).

To learn more about research offerings from Zacks Investment Research, browse through

This instant news alert was generated by narrative scientific research innovation and financial data from Market in order to offer visitors with the fastest as well as most exact reporting. This story was assessed by Market’s content group before magazine. 



Prior to you consider Onconova Therapeutics, you’ll want to hear this.

Market keeps an eye on Wall Street’s top-rated as well as finest executing research analysts as well as the stocks they recommend to their customers each day. Market has actually identified the 5 stocks that top analysts are silently whispering to their customers to buy now prior to the broader market catches on … and also Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics currently has a “Buy” score among experts, premier analysts believe these five stocks are much better gets.